Results 251 to 260 of about 14,072,748 (310)

Nivolumab Induced Reactivation of Hepatitis B in a Patient with Metastatic Gastric Adenocarcinoma-A Case Report. [PDF]

Reports (MDPI)
Kaur JN, Padhi P, Dodeja A.
europepmc   +1 more source

Monitoring of the Cascade of Care in Patients With Chronic HBV in Primary Care Clinics in Australia. [PDF]

J Viral Hepat
Moussa D, Wallace J, Richmond J, Doyle JS, Nguyen L, Boyle D, Stoové MA, Asselin J, Polkinghorne V, Ahad M, Glasgow S, New K, Sanci L, Penn M, Furler J, Thompson A, Hellard M, Howell J.   +17 more
europepmc   +1 more source

Patient awareness of viral hepatitis infection in Al-Madinah, Saudi Arabia: a cross-sectional study. [PDF]

Sci Rep
Elnawasany S, Afghani A, Alqahtani R, Almaimani R, AlKuhayli ST, AlShanqiti ZA, AlAhmadi SA, AlSharif FA, AlHarbi WA, AlOufi AA.   +9 more
europepmc   +1 more source

HIV and Hepatitis B co-infection in Tanzania: Analysis of the 2022-2023 Tanzania HIV Impact Survey. [PDF]

PLoS One
Mwakasungura F, Mwasangama A, Amani D, Bukundi E, Sunguya B.   +4 more
europepmc   +1 more source

Assessment of Immunization Levels in Children with Chronic Diseases in a Tertiary Hospital. [PDF]

Vaccines (Basel)
Ersoy M, Ulukol B.
europepmc   +1 more source

Absence of Detectable Anti-HDV Antibodies Among HBsAg-Positive Blood Donors, HIV-Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay. [PDF]

J Viral Hepat
Nishiya AS, Alencar CS, Gouvea MSG, Ono SK, Salles NA, Mendrone A, Gnouamozi GE, Nkongolo S, Urban S, Schinazi RF, Bassit L.   +10 more
europepmc   +1 more source

An IFN-a/b receptor 1 promoter variant and hepatitis B virus synergistically increase the susceptibility to chronic hepatitis B

, 2008
Zheng, B, Zhou, J, Huang, J, Yuen, KY, Lu, L   +4 more
core  

Some of the next articles are maybe not open access.

Related searches:

Chronic hepatitis B

Current Treatment Options in Gastroenterology, 2004
Interferon alpha, lamivudine, and adefovir are the three drugs currently approved for the treatment of chronic hepatitis B virus (HBV). There are pros and cons associated with the use of each drug. Individualization of therapy, based upon factors such as patient comorbidities, response to prior therapies, and stage of disease, is recommended.
Stephanie D, Straley, Norah A, Terrault
openaire   +2 more sources